Objective: For more than a century, developing novel and effective vaccines against malaria and Tuberculosis (TB) infections has been a challenge. This review sought to investigate the reasons for the slow progress of malaria and TB vaccine candidates in sub-Saharan African clinical trials.
Methods: The systematic review protocol was registered on PROSPERO on July 26, 2023 (CRD42023445166). The research articles related to the immunogenicity, efficacy, or safety of malaria or TB vaccines that were published between January 1, 2012, and August 31, 2023, were searched on three databases: Web of Science (WoS), PubMed, and ClinicalTrials.gov.
Results: A total of 2342 articles were obtained, 50 of which met the inclusion criteria. 28 (56%) articles reported on malaria vaccine attributes, while 22 (44%) articles reported on TB vaccines. In both cases, the major challenges in sub-Saharan African clinical trials were immunogenicity and efficacy, rather than safety.
Conclusion: Factors such as population characteristics, pathogen genetic diversity, vaccine nature, strategy, and formulation were associated with slow progress of the malaria and TB vaccine candidates in sub-Saharan African clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0317233 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Impact of COVID-19 on Utilization of Healthcare Services Among People Living with HIV (PLHIV): A Systematic Review.
Medicina (Kaunas)
January 2025
Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Kerey and Zhanibek Khans St. 5/1, Astana 010000, Kazakhstan.
People living with HIV/AIDS have been impacted notably by the COVID-19 pandemic in diverse dimensions. Although some impacts of COVID-19 on PLHIV have been well documented, there is still insufficient research that captures the overall understanding of the implications of COVID-19 for the healthcare utilization among PLHIV. This review aims to evaluate the impact of COVID-19 on PLHIV, narrowing it down to women living with HIV/AIDS.
View Article and Find Full Text PDFAdvancing Sustainable HIV Services Through Integration in Primary Healthcare in Sub-Saharan Africa: A Perspective on Practical Recommendations.
Healthcare (Basel)
January 2025
Rwanda Biomedical Center, Kigali P.O. Box 7162, Rwanda.
Sub-Saharan Africa continues to bear a disproportionate burden of the global HIV epidemic. Integrating HIV services into primary healthcare is a crucial strategy to accelerate progress towards ending the epidemic. However, several challenges hinder effective integration, including underfunding, human resource shortages, infrastructure limitations, weak health systems, and sociocultural factors.
View Article and Find Full Text PDFPredicting home delivery and identifying its determinants among women aged 15-49 years in sub-Saharan African countries using a Demographic and Health Surveys 2016-2023: a machine learning algorithm.
BMC Public Health
January 2025
Department of Health Informatics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Background: Birth-related mortality is significantly increased by home births without skilled medical assistance during delivery, presenting a major risk to the public's health. The objective of this study is to predict home delivery and identify the determinants using machine learning algorithm in sub-Saharan African.
Methods: This study used design science approaches.
A systematic review on malaria and Tuberculosis (TB) vaccine challenges in sub-Saharan African clinical trials.
PLoS One
January 2025
School of Health Sciences, Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia.
Objective: For more than a century, developing novel and effective vaccines against malaria and Tuberculosis (TB) infections has been a challenge. This review sought to investigate the reasons for the slow progress of malaria and TB vaccine candidates in sub-Saharan African clinical trials.
Methods: The systematic review protocol was registered on PROSPERO on July 26, 2023 (CRD42023445166).
Introduction: Dolutegravir is now extensively used in sub-Saharan Africa as a preferred component of antiretroviral therapy (ART). There is a paucity of large studies using routinely collected data from African people living with HIV on dolutegravir-based regimens to inform HIV programmes. We reviewed data in a large programme clinic of people living with HIV on dolutegravir to determine the real-world safety and tolerability of dolutegravir and to describe drivers of treatment discontinuation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!